Home
MYGN
MYGN News

Latest Myriad Genetics Inc. (MYGN) News on May 20, 2025

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

GlobeNewswire

5 days ago

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Argus Research

6 days ago

MYGN: Lowering target price to $3.00

3 of Wall Street’s Favorite Stocks in Dangerous Territory

StockStory

8 days ago

3 of Wall Street’s Favorite Stocks in Dangerous Territory

Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

Insider Monkey

11 days ago

Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

MT Newswires

11 days ago

Myriad Genetics Shares Drop After Downgrade From Wolfe Research

Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Zacks

12 days ago

Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Simply Wall St.

12 days ago

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

MT Newswires

12 days ago

Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

GlobeNewswire

12 days ago

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

Why Myriad Genetics (MYGN) Stock Is Down Today

StockStory

12 days ago

Why Myriad Genetics (MYGN) Stock Is Down Today

MT Newswires

13 days ago

UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

Zacks

13 days ago

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

MT Newswires

13 days ago

Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22

Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...

GuruFocus.com

13 days ago

Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...

Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

13 days ago

Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%

StockStory

13 days ago

Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Zacks

13 days ago

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

GlobeNewswire

13 days ago

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

StockStory

15 days ago

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

3 Unprofitable Stocks Walking a Fine Line

StockStory

18 days ago

3 Unprofitable Stocks Walking a Fine Line

1 Unprofitable Stock to Target This Week and 2 to Be Wary Of

StockStory

19 days ago

1 Unprofitable Stock to Target This Week and 2 to Be Wary Of

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

GlobeNewswire

20 days ago

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

GlobeNewswire

21 days ago

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

GlobeNewswire

24 days ago

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

3 Healthcare Stocks That Concern Us

StockStory

25 days ago

3 Healthcare Stocks That Concern Us

Argus Research

a month ago

MYGN: What does Argus have to say about MYGN?

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

Zacks

a month ago

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

GlobeNewswire

a month ago

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Argus Research

a month ago

MYGN: What does Argus have to say about MYGN?

Myriad Genetics price target lowered to $9 from $11 at BofA

TipRanks

a month ago

Myriad Genetics price target lowered to $9 from $11 at BofA

MT Newswires

a month ago

Guggenheim Downgrades Myriad Genetics to Neutral From Buy

Argus Research

a month ago

MYGN: Lowering target price to $8.00

Myriad Genetics Announces Inducement Awards

GlobeNewswire

a month ago

Myriad Genetics Announces Inducement Awards

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

GlobeNewswire

a month ago

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Argus Research

2 months ago

MYGN: Lowering target price to $9.00

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?

Zacks

2 months ago

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Zacks

2 months ago

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Argus Research

2 months ago

MYGN: What does Argus have to say about MYGN?

1 Small-Cap Stock on Our Watchlist and 2 to Avoid

StockStory

2 months ago

1 Small-Cap Stock on Our Watchlist and 2 to Avoid

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

StockStory

2 months ago

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

StockStory

2 months ago

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

MT Newswires

2 months ago

Myriad Genetics Shares Rise After Upgrade From Piper Sandler

Why Are Myriad Genetics (MYGN) Shares Soaring Today

StockStory

2 months ago

Why Are Myriad Genetics (MYGN) Shares Soaring Today

MT Newswires

2 months ago

Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory

2 months ago

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results

Simply Wall St.

3 months ago

US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results

Argus Research

3 months ago

MYGN: Lowering target price to $8.00

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

StockStory

3 months ago

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

GlobeNewswire

3 months ago

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

3 months ago

Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations

Argus Research

3 months ago

MYGN: Lowering target price to $9.00

Why Myriad Genetics (MYGN) Shares Are Plunging Today

StockStory

3 months ago

Why Myriad Genetics (MYGN) Shares Are Plunging Today

Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer

Insider Monkey

3 months ago

Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer

MT Newswires

3 months ago

UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating

MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down

Zacks

3 months ago

MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Myriad Genetics Inc Earnings Call

MT Newswires

3 months ago

Myriad Genetics Appoints Sam Raha as Chief Executive

MT Newswires

3 months ago

Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated

Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

3 months ago

Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

3 months ago

Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Zacks

3 months ago

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Associated Press Finance

3 months ago

Myriad: Q4 Earnings Snapshot

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

GlobeNewswire

3 months ago

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

StockStory

3 months ago

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

GlobeNewswire

3 months ago

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Argus Research

3 months ago

MYGN: Raising target price to $12.00

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

GlobeNewswire

3 months ago

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

StockStory

3 months ago

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

MYGN Stock Might Rise on Collaboration With CancerCARE

Zacks

3 months ago

MYGN Stock Might Rise on Collaboration With CancerCARE

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

GlobeNewswire

3 months ago

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

MT Newswires

3 months ago

Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

GlobeNewswire

3 months ago

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

GlobeNewswire

3 months ago

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Argus Research

3 months ago

MYGN: What does Argus have to say about MYGN?

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

GlobeNewswire

4 months ago

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Argus Research

4 months ago

MYGN: What does Argus have to say about MYGN?

Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?

Insider Monkey

4 months ago

Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?

MYGN Stock Gains Following the Launch of Know More Sooner

Zacks

4 months ago

MYGN Stock Gains Following the Launch of Know More Sooner

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

GlobeNewswire

4 months ago

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Argus Research

4 months ago

MYGN: Rating decreased to a SELL

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

GlobeNewswire

4 months ago

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

MT Newswires

4 months ago

Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

GlobeNewswire

4 months ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Argus Research

4 months ago

MYGN: Lowering target price to $14.00

MYGN Stock Gains Following Collaboration With Hannah Storm

Zacks

4 months ago

MYGN Stock Gains Following Collaboration With Hannah Storm

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

GlobeNewswire

4 months ago

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

4 months ago

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

4 months ago

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

4 months ago

Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

GlobeNewswire

4 months ago

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

GlobeNewswire

4 months ago

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price

Simply Wall St.

5 months ago

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price

Argus Research

5 months ago

MYGN: Rating increased to a HOLD

MYGN Stock Might Gain From the New Recognition of RiskScore Study

Zacks

5 months ago

MYGN Stock Might Gain From the New Recognition of RiskScore Study

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

GlobeNewswire

5 months ago

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Argus Research

5 months ago

MYGN: Lowering target price to $11.00

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Zacks

5 months ago

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

MT Newswires

5 months ago

Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend

Argus Research

5 months ago

MYGN: Lowering target price to $12.00

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

GlobeNewswire

5 months ago

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Share on Social Networks: